Skip to main content
THE BCL-2 INHIBITOR ABT-199 (GDC-0199) IS ACTIVE AND WELL-TOLERATED IN ULTRA HIGH-RISK RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.